Aeglea BioTherapeutics Inc

-0.02 (-3.64%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)32.42M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.2 Million
Adjusted EPS-$0.24
See more estimates
10-Day MA$0.50
50-Day MA$0.50
200-Day MA$1.85
See more pivots

Aeglea BioTherapeutics Inc Stock, NASDAQ:AGLE

805 Las Cimas Parkway, Suite 100, Austin, Texas 78746
United States of America
Phone: +1.512.942.2935
Number of Employees: 101


Aeglea Biotherapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.